Fig. 5
Aβ1–42 administration does not induce alterations in locomotor activity, anxiety, and depression-like behavior. Behavioral tasks to evaluate general health state were carried out on days 15–17 post-icv. injection. A Stereotyped behaviors were assessed using a LABORAS® system, measuring the time (in s) spent performing each type of activity (locomotion, climbing, rearing, and grooming). B Latency (in s) to fall off the Rotarod during the six trials (left) and the whole session (right). C Number of entries in closed and total arms were used as measure of locomotor activity (left), while anxiety levels were assessed by the percentage (%) of entries and time spent on open arms in an elevated plus maze (right). D Depression-like behavior was assessed by measuring the immobility time (in s) during a single session in the tail suspension test. N vehicles: males = 8–11 and females = 11–12; N Aβ1–42: males = 8–11 and females = 9–12; N reverse Aβ42–1: males = 7 and females = 6). Aβ, Amyloid-β; s, seconds